Vanguard Group Inc. Buys 841,618 Shares of Organogenesis $ORGO

Key Points

• Vanguard Group Inc. increased its stake in Organogenesis by 23.4% during the first quarter, acquiring an additional 841,618 shares for a total ownership of 4,431,414 shares valued at approximately $19.14 million.
• Several institutional investors, including Mackenzie Financial Corp and Cerity Partners LLC, increased their stakes in Organogenesis, reflecting growing interest in the company's stock.
• Organogenesis reported a loss per share of ($0.09) in its last earnings report, missing analysts' expectations, with revenue of $101.01 million, below the forecast of $104.75 million.

Vanguard Group Inc. raised its holdings in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 23.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,431,414 shares of the company's stock after acquiring an additional 841,618 shares during the quarter. Vanguard Group Inc. owned approximately 3.49% of Organogenesis worth $19,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the business. Merit Financial Group LLC purchased a new stake in shares of Organogenesis during the first quarter worth about $45,000. Victory Capital Management Inc. purchased a new stake in Organogenesis during the 1st quarter valued at approximately $67,000. ProShare Advisors LLC grew its holdings in Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after buying an additional 6,689 shares in the last quarter. Algert Global LLC bought a new stake in shares of Organogenesis during the fourth quarter valued at approximately $69,000. Finally, PDT Partners LLC purchased a new position in shares of Organogenesis in the fourth quarter worth $110,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Lori Freedman purchased 9,022 shares of the business's stock in a transaction dated Friday, June 6th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $26,975.78. Following the completion of the purchase, the insider owned 846,459 shares in the company, valued at approximately $2,530,912.41. This represents a 1.08% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 33.00% of the company's stock.

Organogenesis Price Performance

Shares of Organogenesis stock traded up $0.07 on Thursday, reaching $5.03. The company had a trading volume of 1,266,777 shares, compared to its average volume of 701,069. The firm has a market cap of $638.11 million, a price-to-earnings ratio of -35.93 and a beta of 1.75. The firm's 50-day moving average price is $4.59 and its two-hundred day moving average price is $4.21. Organogenesis has a 1 year low of $2.45 and a 1 year high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The company had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. BTIG Research reaffirmed a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Cantor Fitzgerald upped their price objective on Organogenesis from $7.00 to $9.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $7.50.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.